Mark Holbrook

General Principles for the Validation of Proarrhythmia Risk Prediction Models: An Extension of the CiPA <i>In Silico</i> Strategy

Zhihua Li, Gary R. Mirams, Takashi Yoshinaga et al. · Clinical Pharmacology & Therapeutics · 2019 · 116 citations · Full text

Pharmacy, Cardiology, Pharmacology +9

Best practice in the conduct of key nonclinical cardiovascular assessments in drug development: Current recommendations from the Safety Pharmacology Society

D.J. Leishman, Thomas W. Beck, Noël Dybdal et al. · Journal of Pharmacological and Toxicological Methods · 2011 · 103 citations

Medicine, Cardiology, Pharmacology +10

The inhibition of antigen‐induced eosinophilia and bronchoconstriction by CDP840, a novel stereo‐selective inhibitor of phosphodiesterase type 4

B. Hughes, D. Howat, H. Lisle et al. · British Journal of Pharmacology · 1996 · 95 citations · Full text

Medicine, Immunology, Pharmacology +15

Zebrafish assays as early safety pharmacology screens: Paradigm shift or red herring?

William S. Redfern, Gareth Waldron, Matthew J. Winter et al. · Journal of Pharmacological and Toxicological Methods · 2008 · 69 citations

Pharmacy, Pharmacology, Toxicology +10

Safety pharmacology investigations in toxicology studies: An industry survey

Simon Authier, Hugo M. Vargas, Michael J. Curtis et al. · Journal of Pharmacological and Toxicological Methods · 2013 · 57 citations

Pharmacy, Pharmacology, Toxicology +13